References
- ADLER, C. H., SETHI, K. D., HAUSER, R. A., DAVIS, T. L., HAMMERSTAD, J. P., BERTONI, J., TAYLOR, R. L., SANCHEZ -RAMOS, J. and O'BRIEN, C. F.,1997, Ropinirole for the treatment of early Parkinson's disease. Neurology, 49, 393–399.
- BEATTIE, I. G. and BLAKE, T. G. A., 1989, Application of thermospray liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry for the identification of cynomolgus monkey and human metabolites of SK&F 101468, a dopamine D2 receptor agonist. Journal of Chromatography, 474, 123–138.
- BEERAHEE, A., NICHOLS, A. I., ALURI J., DARWISH M., MCCORMAK, P., CITERONE, D., TAYLOR, A. C. and KREIDER, M., 1997, Population pharmacokinetics of ropinirole in patients with Parkinson's disease. Proceedings of the British Journal of Clinical Pharmacology, 43, 525P–557P.
- BLOOMER, J. C., CLARKE, S. E. and CHENERY, R. J., 1997, In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metabolism and Disposition, 25, 840–844.
- BOPPANA, V. K., FONG, K. L., ZlEMNIAK, A. J. and LYNN, R. K., 1986, Use of a post column immobilised f3-glucuronidase enzyme reactor for the determination of diastereomeric glucuronides of fenoldapam in plasma and urine by HPLC with electrochemical detection. Journal of Chromatography, 353, 231–247.
- BOWEN, W. P., COLDWELL, M. C. and HICKS, F. R., 1993, Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D, receptors. British Journal of Pharmacology, 110, 93P.
- BROOKS, D. J., TORIANSKI, N. and BURN, D. J., 1995, Ropinirole in the symptomatic treatment of Parkinson's disease. Journal of Neural Transmission, Suppl. 45, 231–238.
- CHENERY, R. J., KEOGH, J. P., RATH, L. C. and McWILL1Ams, P., 1991, In vitro-in vivo extrapolation of xenobiotic metabolism. Alternative Methods in Toxicology, 8, 135–143.
- COLDWELL, M. C., HAGEN, J., MIDDLEMISS, D., TuLLocH, I. and BOYF1ELD, I., 1996, Ropinirole is a D, selective agonist at cloned D,10., D, and Dz, z, receptors in functional studies using micro-physiometry. . British Journal of Plarmacology, 119, 346P.
- EDEN, R. J., COSTALL, B., DOMENAY, A. M., GERRARD, P. A., HARVEY, C. A., KELLY, M. E., NAYLOR, R. J., OWEN, D. A. A. and WRIGHT, A., 1991, Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D, agonist. Pharmacology and Biochemical Behaviour, 38, 147–154.
- FEARS, R., BOW, W. P., BROWN, F., COLDWELL, M. C. and RILEY, G. J., 1993, The novel dopaminergic agent ropinirole selectively binds to cloned dopamine D, receptors. Canadian Journal of Neurological Science, 20 (Suppl. 4), S68.
- H's, J. R., 1987, Synthesis of 4- [2 -(di-n-propylamino)ethy1]- [2 -' C]-2(3H)-indolone. Journal of Labelled Compounds and Radiopharmaceuticals, XXIV, 157.
- KREIDER, M., KNOX, S., GARDINER, D. and WHEADON, D., 1996, A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease. Neurology, 46 (Suppl. 2), A475.
- LEHMAN, J. P., FERRIN, L., FENSELAU, C. and YOST, G. S., 1981, Simultaneous immobilisation of cytochrome P-450 and glucuronyltransferase for synthesis of drug metabolites. Drug Metabolism and Disposition, 9, 15–18.
- A/Iwo, B. A., SWAGZDIS, J. E., FEDEROWICZ, D. A. and STRAUB, K., 1986, Functional group metabolism of dopamine-2 agonists : conversion of 4-(2-di-n-propylaminoethyl)-2-(3H)-indolone to 4-(2-di-n-propylaminoethyl)-7-hydroxy-2-(3H)-indolone. Journal of Pharmaceutical Sciences, 75, 929–933.
- TAYLOR, A. C., BEERAHEE, A., CITERONE, D. R., MILLER, A. and FUELL, D., 1998, Linear pharma-cokinetics of ropinirole in patients with Parkinson's disease. Proceedings of the British Journal of Clinical Pharmacology, 45, 204P.